{
  "meta": {
    "timestamp": "2025-01-06T14:18:36.315740",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Avidity Biosciences Inc.",
      "symbol": "RNA",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Regulatory Risks: Potential delays or rejections from the FDA and EMA",
            "Clinical Trial Risks: Negative outcomes from ongoing and future clinical trials",
            "Financial Sustainability: Heavy reliance on external funding for R&D and clinical trials",
            "Market Competition: Intense competition in the biotech landscape",
            "Partial Clinical Hold: Recent FDA partial clinical hold on one of Avidity\u2019s programs"
          ],
          "controversies": [
            "Partial Clinical Hold: Recent FDA partial clinical hold on one of Avidity\u2019s programs"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Ethical Commitment: Active engagement with patient communities and advocacy groups"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Avidity Biosciences Reports Third Quarter 2024 Financial ... - BioSpace",
              "snippet": "SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801303+00:00",
              "published_date": null,
              "source_hash": "5b06ed6e26851024c4ac303e7243012d"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Announces New Precision Cardiology Development ...",
              "snippet": "inadequate efficacy of, Avidity's product candidates that may delay or limit their development, regulatory approval and/or commercialization; Avidity's approach to the discovery and development of product candidates based on its AOC\u2122 platform is unproven; potential delays in the commencement, enrollment,",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801329+00:00",
              "published_date": null,
              "source_hash": "df2702c4ed369fdda99de57e1edf2988"
            },
            {
              "url": "",
              "title": "Why Avidity Biosciences Zoomed to a 12% Gain This Week",
              "snippet": "Clinical-stage biotech Avidity Biosciences (NASDAQ: RNA) had some good news to report toward the end of this week, and investors rewarded it by piling into the company's stock. By the close of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801335+00:00",
              "published_date": null,
              "source_hash": "f7fca1e7a09344189fb996c507b1b7d1"
            },
            {
              "url": "",
              "title": "Avidity Biosciences' Clinical Advancements Positioning for Regulatory ...",
              "snippet": "Avidity Biosciences' Clinical Advancements Positioning for Regulatory Success. TipRanks. Nov. 11, 2024, 12:27 AM. ... Avidity Biosciences Inc is a bio-technology company. The company develops ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801339+00:00",
              "published_date": null,
              "source_hash": "767493bee15f17de6db347cb7e84f07e"
            },
            {
              "url": "",
              "title": "Avidity Biosciences - Crunchbase Company Profile & Funding",
              "snippet": "Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801342+00:00",
              "published_date": null,
              "source_hash": "72351b7a55dad6e124ba294476cb0c0d"
            },
            {
              "url": "",
              "title": "Avidity Biosciences NasdaqGM:RNA Stock Report - Simply Wall St",
              "snippet": "Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics ... Data is normalised which can introduce a delay from the source being available. Package Data Timeframe Example US Source ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801346+00:00",
              "published_date": null,
              "source_hash": "05e4788a109bcd0d476266cc1d4a7577"
            },
            {
              "url": "",
              "title": "Home - Avidity Biosciences",
              "snippet": "At Avidity Biosciences, we are driven by our mission: to profoundly improve people's lives by revolutionizing a new class of targeted RNA therapeutics. We are doing this by realizing the broad and disruptive potential of our Antibody Oligonucleotide Conjugates (AOC \u2122) platform. Beginning with our muscle disease franchise, our programs ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802427+00:00",
              "published_date": null,
              "source_hash": "1d3cbdf78f21ccdabe8bd23062ba9b8f"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial ...",
              "snippet": "SAN DIEGO, Feb. 28, 2023 / / -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to ... product candidates that may delay or limit their development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims; Avidity is early in its development efforts ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801353+00:00",
              "published_date": null,
              "source_hash": "7c5796019a8f29f21dc69be590340788"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Inc - Company Profile and News",
              "snippet": "Avidity Biosciences, Inc. operates as a biotechnology company. The Company develops and discovers antibody oligonucleotide conjugates (AOC) platform to design, engineer, and develop therapeutics ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844429+00:00",
              "published_date": null,
              "source_hash": "954f197c91cbc826e19e98e5750d51ba"
            },
            {
              "url": "",
              "title": "Utah's Top 25 High Impact Biotechnology Companies - Inven",
              "snippet": "Quansys Biosciences is a company that offers custom assay kits, assay printing, and assay development services. They provide multiplex and singleplex assays, sample testing, and imaging software. Their products and services are customizable and tailored to fit the research needs of their customers.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:07.801360+00:00",
              "published_date": null,
              "source_hash": "a73e253a0cf219a97ecd719a19c13c23"
            },
            {
              "url": "",
              "title": "Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?",
              "snippet": "We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against the other multibagger stocks.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. regulatory delays or rejections",
              "retrieved_at": "2025-01-06T21:18:10.363176+00:00",
              "published_date": "2025-01-01T18:12:31+00:00",
              "source_hash": "51c820eb696474f4d29ce347d1afd1c4"
            },
            {
              "url": "",
              "title": "What 8 Analyst Ratings Have To Say About Avidity Biosciences",
              "snippet": "Throughout the last three months, 8 analysts have evaluated Avidity Biosciences RNA, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:22.402093+00:00",
              "published_date": "2024-12-20T11:00:00+00:00",
              "source_hash": "b65d61c367a5a2503ca2b41a4e046ec8"
            },
            {
              "url": "",
              "title": "Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of \"Buy\" by Analysts",
              "snippet": "Shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have earned a consensus rating of \"Buy\" from the eleven analysts that are presently covering the firm, MarketBeat.com reports. Eleven analysts have rated the stock with a buy recommendation.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:22.402080+00:00",
              "published_date": "2025-01-02T08:20:00+00:00",
              "source_hash": "c4e092155e187f79abaf0e5af0637627"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Inc (RNA) Stock Posted a Gross Margin of 73.78% Over the Past Year: Is This Justifiable?",
              "snippet": "Avidity Biosciences Inc (RNA) stock saw a decline, ending the day at $29.18 which represents a decrease of $-0.93 or -3.09% from the prior close of $30.11. The stock opened at $29.8 and touched a low of $28.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:22.402114+00:00",
              "published_date": "2024-12-31T21:18:00+00:00",
              "source_hash": "a0594990605da4a5ebf96ce3641999d2"
            },
            {
              "url": "",
              "title": "Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?",
              "snippet": "Avidity Biosciences, Inc. (RNA) shares ended the last trading session 15% higher at $12.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:22.402105+00:00",
              "published_date": "2024-01-29T19:58:00+00:00",
              "source_hash": "5bc652996c443835d151af26b872d93e"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Announces FDA Removed Partial Clinical ... - Nasdaq",
              "snippet": "About Avidity Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs\u2122). Avidity is ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844414+00:00",
              "published_date": null,
              "source_hash": "755a94f84749166bacb1a07fef00d72f"
            },
            {
              "url": "",
              "title": "Avidity Biosciences, Inc. (Form: 10-K, Received: 03/15/2021 16:20:13)",
              "snippet": "AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ... in a Phase 3 clinical trial by Amicus Therapeutics, Inc., and neoGAA in a Phase 3 clinical trial by Sanofi Genzyme. In addition, several companies are ... Failure to comply with the applicable U.S. requirements at any time during the product development process ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802339+00:00",
              "published_date": null,
              "source_hash": "541a3c74c2bbd4575d075eb95f21270a"
            },
            {
              "url": "",
              "title": "Why Avidity Biosciences Zoomed to a 12% Gain This Week",
              "snippet": "Partial clinical hold released. On Thursday, Avidity announced that the U.S. Food and Drug Administration (FDA) has released its partial clinical hold on one of the biotech company's ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802354+00:00",
              "published_date": null,
              "source_hash": "7f0dd969e5d91e4bab5ba6876471db85"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Pursues Potential Accelerated Approval Path with ...",
              "snippet": "Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802364+00:00",
              "published_date": null,
              "source_hash": "22627a32cda352387c2b16fcdb0432c7"
            },
            {
              "url": "",
              "title": "Why Avidity Biosciences Zoomed to a 12% Gain This Week - Yahoo Finance",
              "snippet": "Clinical-stage biotech Avidity Biosciences ... The drug is being tested in a phase 3 clinical trial. In 2022, the FDA placed its hold following news of a patient experiencing a serious adverse ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802374+00:00",
              "published_date": null,
              "source_hash": "d72b46354f36b91d3221477cf85c09a8"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Announces New Precision Cardiology Development ...",
              "snippet": "approval and/or commercialization; Avidity's approach to the discovery and development of product candidates based on its AOC\u2122 platform is unproven; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies or clinical trials; Avidity's dependence on third parties in",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802384+00:00",
              "published_date": null,
              "source_hash": "a0d156350c4d01555f4b978a688905f4"
            },
            {
              "url": "",
              "title": "Avidity Biosciences' SWOT analysis: RNA stock poised for growth in ...",
              "snippet": "How might clinical trial failures impact RNA's future? ... 2024, and reflects the most recent data and projections provided by financial analysts covering Avidity Biosciences, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802396+00:00",
              "published_date": null,
              "source_hash": "f0be3e815b1d12da0bb55f7f40a48241"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Announces FDA Partial Clinical Hold on New ... - Nasdaq",
              "snippet": "--Avidity Biosciences, Inc., ... and Drug Administration has placed a partial clinical hold on new participant enrollment in the Phase 1/ 2 MARINA\u2122 clinical trial of AOC 1001 in adults with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802405+00:00",
              "published_date": null,
              "source_hash": "1b257d729706a694f6a3348c3efd1ca2"
            },
            {
              "url": "",
              "title": "Expanded Access - Avidity Biosciences",
              "snippet": "Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of investigational RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122). Expanded Access refers to the use of an investigational therapy outside a clinical trial for potential treatment of a serious condition in a patient.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:13.802416+00:00",
              "published_date": null,
              "source_hash": "31143e95a05ab83c716239935be5e736"
            },
            {
              "url": "",
              "title": "Avidity Biosciences (NASDAQ:RNA) Trading Down 5.4% - Here's What Happened",
              "snippet": "Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) shares fell 5.4% during trading on Monday . The stock traded as low as $28.36 and last traded at $28.48. 475,265 shares traded hands during mid-day trading,",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:16.360591+00:00",
              "published_date": "2024-12-30T19:24:00+00:00",
              "source_hash": "f3a04774862a6ca022e76ee704034f3f"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
              "snippet": "SAN DIEGO, Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that on November 20 ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:16.360601+00:00",
              "published_date": "2024-11-21T00:00:00+00:00",
              "source_hash": "d0db6542609a7ad79fef33284f6eb45d"
            },
            {
              "url": "",
              "title": "Home - Avidity Biosciences",
              "snippet": "At Avidity Biosciences, we are driven by our mission: to profoundly improve people's lives by revolutionizing a new class of targeted RNA therapeutics. ... Our innovative pipeline is set to advance and expand into additional cells and tissues, allowing us to address unmet patient needs across a wide-range of therapeutic areas. Platform ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844285+00:00",
              "published_date": null,
              "source_hash": "dba1536e1c43bbe5c971160b7f9da823"
            },
            {
              "url": "",
              "title": "Patients - Avidity Biosciences",
              "snippet": "At Avidity, we strive to incorporate patient and family voices into everything we do. We understand that living with a rare disease presents many challenges for patients and their families and we are committed to listening, learning, and partnering with the patient and advocacy community.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844399+00:00",
              "published_date": null,
              "source_hash": "7435bea815b3557c478e523f0dbc4117"
            },
            {
              "url": "",
              "title": "Why Avidity Biosciences Zoomed to a 12% Gain This Week",
              "snippet": "Avidity did not disclose the nature of that event, banning the recruitment of new patients. The regulator relaxed that hold, allowing the company to restart recruitment. The current phase 3 trial ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844440+00:00",
              "published_date": null,
              "source_hash": "5e4d0ca3deeffa9b8cd246435ce4d1f0"
            },
            {
              "url": "",
              "title": "Avidity Biosciences - BioSpace",
              "snippet": "Shares of Avidity Biosciences are soaring following reported early signs of clinical activity and improvement in patients with myotonic dystrophy type 1 (DM1) treated with its RNA-based therapeutic. ... Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844449+00:00",
              "published_date": null,
              "source_hash": "8aa8db6903031cf92d99c947984ff0f1"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Reviews: What Is It Like to Work At Avidity ...",
              "snippet": "Avidity Biosciences has an overall rating of 4.3 out of 5, based on over 16 reviews left anonymously by employees. 85% of employees would recommend working at Avidity Biosciences to a friend and 81% have a positive outlook for the business. This rating has improved by 7% over the last 12 months.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844458+00:00",
              "published_date": null,
              "source_hash": "16affdf196ef9a8feb462ee6d14d8a68"
            },
            {
              "url": "",
              "title": "Avidity Biosciences to Participate in Upcoming Investor Conference",
              "snippet": "--Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, today announced that Avidity management ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844467+00:00",
              "published_date": null,
              "source_hash": "43a413dbbe4c44dafad9b1ce904a49d7"
            },
            {
              "url": "",
              "title": "Avidity Biosciences - Company Profile - Tracxn",
              "snippet": "Avidity Biosciences - Develops antibody-siRNA complexes to treat cancer. Public Company. Raised a total funding of $143M over 7 rounds from 21 investors. Founded by Troy Wilson and Kent Hawryluk in the year 2012. ... Developer of selective kinase inhibitors for patients with genomically defined cancers. $115M. Ridgeback Capital Management, ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844476+00:00",
              "published_date": null,
              "source_hash": "fa675a6512dfea4eb63429dc9e7aa668"
            },
            {
              "url": "",
              "title": "Avidity Biosciences Inc | Reuters",
              "snippet": "Avidity Biosciences Inc said on Tuesday the U.S. Food and Drug Administration has put a hold on patient enrollment in an early-to-mid-stage trial of its drug to treat a genetic muscle disorder ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:19.844487+00:00",
              "published_date": null,
              "source_hash": "d5e8bde94ef3715ef977d37c25da995d"
            },
            {
              "url": "",
              "title": "Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?",
              "snippet": "In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against the other multibagger stocks. The US equities continued their upward movement in 2024 ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Avidity Biosciences Inc. Avidity Biosciences Inc. patient advocacy controversies",
              "retrieved_at": "2025-01-06T21:18:22.401998+00:00",
              "published_date": "2025-01-01T23:29:00+00:00",
              "source_hash": "e114c74ebd25d0835ebba07ed255e262"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Avidity Biosciences Inc. regulatory delays or rejections",
              "rationale": "Investigate potential regulatory challenges impacting product approvals",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Avidity Biosciences Inc. clinical trial failures",
              "rationale": "Assess risks related to negative outcomes in ongoing or completed clinical trials",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Avidity Biosciences Inc. patient advocacy controversies",
              "rationale": "Explore any ethical concerns or disputes with patient advocacy groups",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:18:36.315745",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}